Aligos Therapeutics appoints Lesley Ann Calhoun as COO while retaining CFO role

Aligos Therapeutics, Inc.

Lesley Ann Calhoun appointed COO effective January 30, 2025, adding to existing CFO role.
She has served as EVP and CFO since June 2020; prior roles at Global Blood Therapeutics and Hyperion Therapeutics.
Calhoun brings over 30 years of finance and operations experience, including audit at Deloitte & Touche.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Lesley Ann Calhoun

Chief Operating Officer

ALGS · Aligos Therapeutics, Inc.

Effective: 2025-01-30
Filed: February 3, 2025, 6:59 PM ET

On January 30, 2025, the Board of Directors of Aligos Therapeutics, Inc. (the “Company”) appointed Lesley Ann Calhoun as the Company’s Chief Operating Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lesley Ann Calhoun was appointed as Chief Operating Officer at Aligos Therapeutics, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On January 30, 2025, the Board of Directors of Aligos Therapeutics, Inc. (the “Company”) appointed Lesley Ann Calhoun as the Company’s Chief Operating Officer, effective immediately.

View on SEC.gov

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-019256

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.